Research results published in the American Journal of Obstetrics and Gynecology suggest that virtual care visits can be effective for detecting abnormal endometrial cancer-related vaginal bleeding ...

A study of 162,500 patients with uterine cancer found that survival rates varied significantly by race and geographic location, with Black patients experiencing the worst survival outcomes in ...

Endometrial cancer is the most common gynecological cancer in highly-developed countries, most often affecting women after menopause. The majority of women are diagnosed at an early stage ...

JACKSONVILLE, Fla. — Uterine cancer cases are on the rise in the United States and experts are paying close attention to the higher rates of death and later diagnosis for Black women.

First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non–Small-Cell Lung Cancer: A ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

NOTE. These are the baseline variables determined at treatment completion and included in the analysis. Abbreviations: CIN, cervical intraepithelial neoplasia; COPD, chronic obstructive pulmonary ...

PapSEEK, a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Vienna, Austria – Endometrial cancer is the most common gynecological cancer in high-developed countries, most often affecting women after menopause. The majority of women are diagnosed at an ...

kidney and uterine cancers. Scientists from the National Cancer Institute looked at data that included more than 2 million cancers diagnosed in people 15 to 49 years old between 2010 and 2019.